Subarachnoid Bupivacaine in Obese Patients Undergoing Cesarean Delivery
Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of subarachnoid hyperbaric bupivacaine on mean arterial blood
pressure (MAP) of pregnant patients with obesity undergoing cesarean section half of the
patients will receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg while the other
half will receive a dose of 10 mg